Baiyang Pharmaceutical metformin new drug Nida in the United States approved by the FDA

recently, baiyangPharmaceutical(http://announced that thecompany(http://of high-end generic drugs, the use of osmosis pump-controlled release technology metforminnew drug(http://the United States was approved by theFDA(http://future, theproduct(http://will also be available in China, which is expected to become the first permeable pump form in ChinaWhen it comes to oral anti-sugar drugs, you have to mention metformin It has been used in clinical practice for 60 years, is the world's most extensive treatment of type 2 diabetes, the most common classic oral sugar-reducing drug (http:// , but also clinically explore the broader indications of one of the most common drugs At present, the research on all aspects of metformin is still under way, and its application value is constantly excavated 　　From the clinical use of metformin form selection, China and the United States there are great differences 　　The U.S market is mainly slow-control release dosage form, the market share reached 94%, while the domestic general release dosage form still dominates, the proportion of slow-control release dosage form is only about 22%, and the permeation pump-controlled release agent form metformin, the market is not 　　Up to now, there is still no osmosis pump-controlled release form metformin listed, because China can master the release of the drug technology is very few, and the quality and efficacy of the original drug is consistent with the high-end generic drugs are even less 　　With the launch of Baiyang Pharmaceuticals' Nida ® in the United States and the upcoming approval of china, it will greatly impact the international and Chinese market for metformin and the entire market for oral anti-sugar drugs